The big success of this class of radiopharmaceuticals is based on Glu-C(O)-Lys(Ahx-[68Ga]Ga-HBED-CC) (68Ga-PSMA-11) [85] (Figure 2), which was introduced for prostate carcinoma (PCa) diagnosis in 2011 [154]. Here, FOLH1 is linked to prostate carcinoma.